Header Logo

Connection

RACHEL SCHIFF to Estrogen Antagonists

Back to Details
This is a "connection" page, showing publications RACHEL SCHIFF has written about Estrogen Antagonists.
RACHEL SCHIFF
Connection Strength
0.392
Estrogen Antagonists
  1. Elacestrant and the Promise of Oral SERDs. J Clin Oncol. 2022 10 01; 40(28):3227-3229.
    View in: PubMed
    Score: 0.184
  2. Upregulation of mucin4 in ER-positive/HER2-overexpressing breast cancer xenografts with acquired resistance to endocrine and HER2-targeted therapies. Breast Cancer Res Treat. 2012 Jul; 134(2):583-93.
    View in: PubMed
    Score: 0.092
  3. Mechanisms of endocrine resistance in breast cancer. Annu Rev Med. 2011; 62:233-47.
    View in: PubMed
    Score: 0.083
  4. Tamoxifen Resistance in Breast Cancer Is Regulated by the EZH2-ERa-GREB1 Transcriptional Axis. Cancer Res. 2018 02 01; 78(3):671-684.
    View in: PubMed
    Score: 0.034
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.